Home | Welcome to Contract Pharma   
Last Updated Thursday, January 29 2015

Print

Search Results for 'Drug Discovery'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Contract Service Directory Companies

View All Companies »


Contract Service Directory Categories

View All Categories »


Search Results:

Published January 22, 2015
Will research and develop approaches to CAR T cell therapy in cancer Read More »
Published January 20, 2015
Aims to improve asset development and delivery timelines Read More »
Published January 19, 2015
To apply discovery and technology platforms to develop inhibitors for addictive disorders Read More »
Published January 14, 2015
Gains exclusive rights to oncology target Read More »
Published January 12, 2015
Will include additional oncology targets Read More »
Published January 9, 2015
Aims to identify new treatment approaches for diseases with significant unmet need Read More »
Published January 9, 2015
Includes cross-license for two programs targeting thrombosis and cardiovascular disease Read More »
Published January 9, 2015
X-Chem will apply its discovery engine to identify novel compounds Read More »
Published January 5, 2015
To develop antisense drugs to treat gastrointestinal autoimmune disorders Read More »
Published December 17, 2014
Includes a series of small molecule compounds against a cardiovascular drug target Read More »
Published December 15, 2014
Broadens access to key biotech hubs Read More »
Published December 11, 2014
X-Chem to identify drug candidates against Alexion targets Read More »
Published December 8, 2014
Will collaborate with Spark to progress SPK-FIX clinical program in hemophilia B Read More »
Published December 4, 2014
Reaffirms commitment to NJ Read More »
Published December 3, 2014
To encompass pipeline-building, outsourcing alliance, and open innovation initiatives Read More »
Published November 18, 2014
Alliance of CMO with leading drug product formulator creates fully integrated CDMO focusing on advanced drug delivery and combination products. Read More »
Published November 17, 2014
Focus of collaboration is to develop an antibody actinium 225 construct using novel labelling technology to enable platform expansion. Read More »
By Derek B. Lowe, Contributing Editor
Published November 13, 2014
These are two worlds that certainly don’t see eye-to-eye. Read More »
Published November 10, 2014
Will provide research activities for another five years Read More »
Published October 30, 2014
Will collaborate with Pontifax to invest in technologies to advance capabilities Read More »
Published October 21, 2014
Adds new immunotherapy platforms for cancer research Read More »
Published October 15, 2014
Will perform drug combination screening on lead oncology asset Read More »
Published October 7, 2014
Successfully nominates oral drug candidate for preclinical development Read More »
Published October 2, 2014
Further expands SMARTag Antibody-Drug Conjugate (ADC) technology platform Read More »
Published September 29, 2014
Expands gene-editing capabilities Read More »
Published September 25, 2014
Sees growth in small molecule discovery technology Read More »
Published September 22, 2014
Silarus Therapeutics and Thyritope Biosciences will receive $10M in financing and R&D support Read More »
Published September 15, 2014
Evotec to provide screening of compound libraries in multiple assay formats Read More »
Published September 8, 2014
Therapeutic antibodies target autoimmune disease Read More »
Published August 19, 2014
Evotec to provide compound management services to support malaria research Read More »
Published July 15, 2014
To employ Fluofarma discovery and translational services Read More »
Published July 8, 2014
Expands Evotec's drug discovery platform Read More »
Published July 3, 2014
To establish library of more than 200,000 compounds Read More »
Published June 23, 2014
Transitions compound into preclinical development Read More »
Published June 11, 2014
X-Chem to apply discovery engine to identify novel leads Read More »
Published June 5, 2014
Will share R&D rights to gene editing technology Read More »
Published June 4, 2014
Shire invests $20.4 million in arGEN-X Read More »
Published June 4, 2014
Will continue to explore new approaches in metabolic disease Read More »
Published May 15, 2014
Adds high-throughput screening, drug combination sciences and bioinformatics expertise Read More »
Published May 9, 2014
Will use CRISPR/Cas9 gene editing system for research applications Read More »
Published May 9, 2014
Aims to develop new experimental cancer models Read More »
Published May 7, 2014
Will align Pharmorphix and BioTools for comprehensive chiral technology services Read More »
Published May 7, 2014
Adds early phase development and CMC services Read More »
Published May 6, 2014
Evotec will employ its drug discovery platform to identify a clinical candidate Read More »
Published May 2, 2014
Will evaluate the microbiome in metabolic diseases Read More »
Published May 1, 2014
Aims to develop new therapeutic approaches to treat MS Read More »
Published April 29, 2014
Gains lead preclinical asset for neurodegenerative diseases Read More »
Published April 16, 2014
Will transition DDS ops to other sites Read More »
Published April 4, 2014
Will be used to enhance infectious disease development program Read More »
Published April 2, 2014
To develop compounds for the potential treatment of cancer Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On